(Taipei Taiwan, May 16, 2022) Pharmosa Biopharm Inc. today announces the presentation of P204/A8350 Poster at 2022 American Thoracic Society (ATS) Conference at San Francisco, CA., titled as “Multicompartment Modeling for Pulmonary Pharmacokinetics of Liposomal Treprostinil (L606) in Adults.
PBI’s multicompartment physiologically-based model was developed to simulate treprostinil levels of L606 and Tyvaso in the pulmonary tissue of healthy adult volunteers. Currently in the market, inhaled treprostinil is delivered with immediate-release formulation. Short half-life results in high peak-trough fluctuation and requires frequent dosing.
Important data derived from this modelling includes:
Disclaimer: Drug development timeline is often long and with uncertainties, many of which are beyond our control. The information contained herein does not constitute a solicitation of any securities. For corporate development and filings, please refer to Taiwan MOPs for public information disclosures.